NCT numbers | Agent | Other agents | Inclusion | Phase | Start | End | Enrollment |
---|---|---|---|---|---|---|---|
NCT02935790 | ACY-241 | Nivolumab | Malignant melanoma | I | 2016.10 | 2017.8 | 1 |
Ipilimumab | |||||||
NCT02635061 | ACY-241 | Nivolumab | NSCLC | I | 2015.12 | 2018.5 | 41 |
NCT01583283 | ACY-1215 | Lenalidomide | Multiple myeloma | I/II | 2012.7 | 2018.11 | 38 |
Dexamethasone | |||||||
NCT01323751 | ACY-1215 | – | Multiple myeloma | I/II | 2011.3 | 2017.4 | 120 |
NCT02091063 | ACY-1215 | – | Lymphoma | I/II | 2014.3 | 2017.5 | 40 |
Lymphoid malignancies | |||||||
NCT02632071 | ACY-1215 | Nab-paclitaxel | Metastatic breast cancer | I | 2015.12 | 2018.2 | 24 |
Breast carcinoma | |||||||
NCT03008018 | KA2507 | – | Solid tumor | I | 2017.8 | 2019.3 | 30 |